Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy

Anna De Bona, Laura Galli, Giulia Gallotta, Aurelia Guzzo, Laura Alagna, Adriano Lazzarin, Caterina Uberti-Foppa

Research output: Contribution to journalArticle

Abstract

This is a retrospective longitudinal follow-up study of 25 HIV/HCV positive cirrhotic patients not responding to peg-IFN plus ribavirin, and 25 untreated controls matched for age (±5 years), gender and Child-Pugh score. The primary endpoint of the study was the incidence of cirrhosis progression (CP) defined as the occurrence of at least one of the following events: death, ascites, jaundice, encephalopathy, gastrointestinal bleeding and hepatocellular carcinoma (HCC). During the median follow-up of 54 months (34-89), four treated (16%) and 13 untreated patients (52%) experienced CP (p=0.02). Poisson's regression model showed that the independent predictors of CP were Peg-IFN therapy (p=0.016), positive HIV-RNA (p=0.024), and altered ALP values (p=0.012). Peg-IFN therapy seems to slow down the rate of cirrhosis progression also in HIV/HCV co-infected patients nonresponders to anti-HCV therapy, in comparison with untreated patients.

Original languageEnglish
Pages (from-to)259-264
Number of pages6
JournalNew Microbiologica
Volume30
Issue number3
Publication statusPublished - Jul 2007

Keywords

  • Cirrhosis progression
  • HIV/HCV co-infection
  • Non-responders
  • Peg-IFN

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy'. Together they form a unique fingerprint.

  • Cite this